The antiviral treatment impacts on clinical outcomes of renal transplantation recipients with hepatitis B virus infection.
- Author:
Zhen-Wei WEI
1
;
Qi-Huan XU
;
Xin SHU
;
Yu-Sheng JIE
;
Ka ZHANG
;
Qi-Feng XIE
;
Gang LI
Author Information
- Publication Type:Journal Article
- MeSH: Adenine; analogs & derivatives; therapeutic use; Adult; Aged; Antiviral Agents; therapeutic use; Case-Control Studies; Female; Hepatitis B; drug therapy; virology; Hepatitis B virus; drug effects; physiology; Humans; Kidney Transplantation; mortality; Lamivudine; therapeutic use; Male; Middle Aged; Organophosphonates; therapeutic use; Treatment Outcome
- From: Chinese Journal of Experimental and Clinical Virology 2009;23(3):224-226
- CountryChina
- Language:Chinese
-
Abstract:
UNLABELLEDOBJECTIVE; To investigate the clinic outcomes and the efficacy of antiviral treatment in renal transplantation recipients with hepatitis B viral serum markers positive.
METHODS32 renal transplantation recipients with hepatitis B viral serum markers positive were enrolled. 23 patients in antiviral treatment group have received the lamivudine (19 cases), enticavir (2 cases) and adefovir (1 case). Another 9 patients have not received the antiviral treatment and were as the control group.
RESULTSThe biochemical response rate in antiviral treatment group and control group is 82.60% and 22.22%, respectively. 19 of 23 (82.60%) patients in treatment group survived and 1 of 9 (11.11%) patients in control group survived (P < 0.05). 20 of 23 (86.95%) patients in treatment group have the reduction of HBV DNA more than 2 log copies/ml or maintain less than 5 log copies/ml, while 1 of 9 (11.11%) patients in control group has the HBV DNA maintain less than 5 log copies/ml (P < 0.05). The virology rebound was observed in 6 of 19 (31.58%) patients with lamivudine treatment. 2 of them shift to enticavir treatment and 1 of them add adefovir treatment. The three patients survived. Other 3 patients die of liver function failure.
CONCLUSIONThe antiviral could improve the survival in renal transplantation recipients with hepatitis B viral serum markers positive. When the virology rebound occurs, the add-on with adefovir or the shift to enticavir could be a rescue treatment.
